Biowaiver monographs for immediate-release solid oral dosage forms: Ketoprofen

Journal of Pharmaceutical Sciences

Volumn 101, Issue 10, 2012, Pages 3593-3603

  Shohin, Igor E ^a,b   Kulinich, Julia I ^a,b   Ramenskaya, Galina V ^a,b   Abrahamsson, Bertil ^c   Kopp, Sabine ^d   Langguth, Peter ^e   Polli, James E ^f   Shah, Vinod P ^g   Groot, D W ^h   Barends, Dirk M ^h   Dressman, Jennifer B ⁱ  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^b Scientific Centre for Expert Evaluation of Medicinal Products   (Russian Federation)

^c ASTRAZENECA R AND D   (Sweden)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY OF MARYLAND   (United States)

^g International Pharmaceutical Federation FIP   (Netherlands)

^h NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

ⁱ GOETHE UNIVERSITY   (Germany)

Author keywords

Absorption; Biopharmaceutics Classification System (BCS); Dissolution; Ketoprofen; Permeability; Regulatory science; Solubility

Indexed keywords

KETOPROFEN; MAGNESIUM HYDROXIDE;

ABDOMINAL PAIN; ACUTE DISEASE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BOOK; COMA; CONSTIPATION; CONTROLLED DRUG RELEASE; CONVULSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DYSMENORRHEA; DYSPNEA; EXCIPIENT COMPATIBILITY; FEVER; FLUID RETENTION; GOUT; HEADACHE; HEARTBURN; HUMAN; HYPERTENSION; HYPOTENSION; IN VITRO STUDY; INTESTINAL BLEEDING; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OSTEOARTHRITIS; PAIN; RASH; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH HEMORRHAGE; STOMACH PAIN; STOMACH ULCER; VOMITING;

EID: 84865384975     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23233     Document Type: Note

References (85)

1. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Möller H, Olling M, Shah VP, Barends DM. 2004. Biowaiver monographs for immediate release solid oral dosage forms based on Biopharmaceutics Classification System (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci 93:1945-1956.
2. World Health Organization (WHO). 2006. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No. 937, 40th Report, Annex 8 of WHO Expert Committee on Specifications for Pharmaceutical Preparations. Accessed August 20, 2010, at: http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf.
3. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2000. Guidances for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Accessed August 20, 2010, at: http://www.fda.gov/CDER/GUIDANCE/3618fnl.pdf.
4. European Medicines Agency, Committee for Medicinal Products for Human Use. 2010. Guideline on the investigation of bioequivalence. Accessed August 20, 2010, at: http://www.ema.europa.eu/docs/enGB/documentlibrary/Scientificguideline/2010/01/WC500070039.pdf.
5. International Pharmaceutical Federation (FIP). 2009. Biopharmaceutics Classification System (BCS). Accessed August 20, 2010, at: http://www.fip.org/bcs.
6. World Health Organization (WHO). 1997. Guidance on INN. Accessed August 20, 2010, at: http://www.who.int/medicines/services/inn/innquidance/en.
7. Merck Research Laboratories. 2005. The Merck Index. 13th ed. Rahway, New Jersey: Merck Research Laboratories.
8. Hayball PJ. 1993. Chirality in clinical pharmacology. Ph.D. Thesis. Adelaide, South Australia, Australia: The University of Adelaide.
9. Leffingwell JC. 2003. Chirality and bioactivity I: Pharmacology. Leffingwell Rep 3(1):1-27.
10. Scientific Center for Expertise of Medical Products Database. Accessed August 20, 2010, at: http://www.regmed.ru/search.
11. U.S. Food and Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). Approved drug products database. Accessed August 20, 2010, at: http://www.accesdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
12. Balani M, Gawade P, Mahesgauri S, Ghole S, Shinde V, Sahte V. 2008. Dexketoprofen in dental pain and dysmenorrhoea. J Clin Diagn Res 2:1086-1091.
13. Tettey-Amlalo R. 2005. In vitro release of ketoprofen from proprietary and extemporaneously manufactured gels. Ph.D. Thesis. Grahamstown, South Africa: Faculty of Pharmacy, Rhodes University.
14. Moffat AC; Osselton DM, Widdop B, Watts J, Eds. 2007. Clarke's analysis of drugs and poisons. Electronic version. London, UK: Pharmaceutical Press. Accessed May 20, 2011, at: http://www.medicinescomplete.com/mc/clarke/2006/.
15. Drug Bank Database. Drug card for ketoprofen. Accessed August 20, 2010, at: http://www.drugbank.ca/drugs/DB01009.
16. Ketoprofen official FDA information, side effects and uses. Accessed July 26, 2010, at: http://www.drugs.com/pro/ketoprofen.html.
17. U.S. Food and Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). 2008. Title 21-Food and Drugs, Chapter I-Subchapter D-Drugs for human use-Part 320-Bioavailability and bioequivalence requirements. Accessed August 20, 2010, at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=320.
18. Health Canada. 2006. Guidance for industry: Bioequivalence requirements: Critical dosage drugs. Accessed May 20, 2011, at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/applic-demande/guide-ld/bio/critical_dose_critique-eng.pdf.
19. National Institute of Health Sciences. 2000. Guideline for bioequivalence studies for different strengths of oral solid dosage forms. Accessed May 20, 2011, at: http://www.nihs.go.jp/drug/be-guide%28e%29/strength/strength.html.
20. Fries JT, Williams CA, Rarmey D, Bloch DA. 1993. The relative toxicity of disease modifying antirheumatic drugs. Arthritis Rheum 36:297-300.
21. Henry D, Lynette LL, Rodriguez LG, Gutthann SP, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT. 1996. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of collaborative meta-analysis. BMJ 312:1563-1566.
22. Tubic-Grozdanis M, Bolger MB, Langguth P. 2008. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J 10(1):213-226.
23. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1:85-96.
24. Chuasuwan B, Binjesoh V, Polli JE, Zhang H, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium. J Pharm Sci 98:1206-1219.
25. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. J Pharm Sci 94:2121-2131.
26. Sheng J, Kasim NA, Chandrasekharan R, Amidon GL. 2006. Solubilization and dissolution of insoluble weak acid, ketoprofen: Effects of pH combined with surfactant. Eur J Pharm Sci 29:306-314.
27. European Directorate for the Quality of Medicines, Council of Europe. 2007. European Pharmacopoeia (Ph. Eur.). 6th ed. Strasbourg, France: European Directorate for the Quality of Medicines, Council of Europe.
28. The Stationery Office on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA). 2007. British Pharmacopoeia (B.P.). London, UK: The Stationery Office on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA).
29. The United Pharmacopeial Convention. 2008. United States Pharmacopeia and National Formulary USP 31-NF 26. Rockville, Maryland: The United Pharmacopeial Convention.
30. Thorsteinn L, Dagný H. 2006. Determination of aqueous solubility by heating and equilibration: A technical note. AAPS PharmSciTech 7(1):E29-E32.
31. Sheng J. 2007. In vitro release of ketoprofen from proprietary and extemporaneously manufactured gels. Ph.D. Thesis. Ann Arbor, Michigan: The University of Michigan.
32. Yazdanian M, Briggs K, Jankovsky C, Hawi A. 2004. The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm Res 21:293-299.
33. Fassen F, Vromans H. 2004. Biowaivers for oral immediate-release products: Implications of linear pharmacokinetics. Clin Pharmacokinet 43(15):1117-1126.
34. Dressman JB, Amidon GL, Reppas C, Shah VP. 1998. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res 15:11-22.
35. World Health Organization (WHO). 2007. Essential Medicines WHO Model List (EML). 15th ed. (revised version March 2007). Accessed August 20, 2010, at: http://www.who.int/medicines/publications/08_ENGLISH_indexFINAL_EML15.pdf.
36. Státní ústav pro kontrolu léčiv. Accessed March 1, 2011, at: (CZ) http://www.sukl.cz.
37. ROTE LISTER®. Arzneimittelverzeichnis fur Deutschland. Accessed March 1, 2011, at: http://www.rote-liste.de.
38. The Danish Medicines Agency. Accessed March 1, 2011, at: http://www.dkma.dk.
39. Agencia Espanola de Medicamentos y Productos Sanitarios. Accessed March 1, 2011, at: http://www.aemps.es.
40. National Agency for Medicines. Accessed March 3, 2011, at: http://www.fimea.fi.
41. VIDAL. Fiches médicaments. Accessed March 2, 2011, at: http://www.vidal.fr.
42. Gyógyszerészeti és Egészségügyi Mino{double acute}ségés Szervezetfejlesztési Intézet. Accessed March 3, 2011, at: http://www.ogyi.hu.
43. Icelandic Medicines Agency. Accessed March 3, 2011, at: http://www.imca.is.
44. College ter Beoordeling van Geneesmiddelen-Medicines Evaluation Board. Accessed March 3, 2011, at: http://www.cbg-meb.nl.
45. Norwegian Medicines Agency. Accessed March 3, 2011, at: http://www.legemiddelverket.no.
46. Autoridade Nacional do Medicamento e Produtos de Saúde. Accessed March 3, 2011, at: http://www.infarmed.pt/infomed/pesquisa.php.
47. Agentia Nationala a Medicamentului si a Dispozitivelor Medicale. Accessed March 3, 2011, at: http://www.anm.ro.
48. Lakemedelsverket. Accessed March 9, 2011, at: http://www.lakemedelsverket.se.
49. Štátny ústav pre kontrolu liečiv. Accessed March 9, 2011, at: http://www.sukl.sk.
50. Datapharm Communications Ltd. Accessed March 9, 2011, at: http://www.medicines.org.uk/emc.
51. DailyMed. Accessed March 9, 2011, at: http://www.dailymed.nlm.nih.gov.
52. Jain RA, Ruddy SB, Cumming KI, Clancy MJA, Codd JE. 2001. Rapidly disintegrating solid oral dosage form. Patent US6316029.
53. Jachowicz R, Nürnbergb E, Pieszczeka B, Kluczykowskaa B, Maciejewskaa A. 2000. Solid dispersion of ketoprofen in pellets. Int J Pharm 206(1-2):13-21.
54. Jamali F, Brocks DR. 1990. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet 19(3):197-217.
55. Kim JS, Mitchell S, Kijek P, Tsume Y, Hilfinger J, Amigdon GL. 2006. The suitability of in situ perfusion model for permeability determinations: Utility for BCS Class I biowaiver requests. Mol Pharm 3(6):686-694.
56. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, Barzegar S, Barzegar-Jalali M. 2007. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci 10(3):368-379.
57. Hilgendorf C, Spahn-Langguth H, Regårdh CG, Lipka E, Amidon GL, Langguth P. 2000. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: Permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci 89(1):63-75.
58. Igonin A, Guillard E, Benameur H. 2006. Development of self-emulsifying systems for class II active compounds. Greenwood, South Carolina: Pharma R&D Center, Capsugel, Division of Pfizer. Accessed August 20, 2010, at: http://www.capsulgel.com/casestudies/bcs/CS-Liquid_Formulation.pdf.
59. Lemke TL, Williams DA, Roche VF, Zito SW. 2008. Foyes principles of medical chemistry. 6th ed. Philadelphia, Pennsylvania: Lippincott Williams and Wilkins.
60. Sanofi-Aventis. Orudis® prescribing information.Paris, France: Sanofi-Aventis. Revision date: 03/2006.
61. Health Canada. Accessed March 1, 2011, at: http://www.hc-sc.gc.ca.
62. U.S. Department of Health and Human Services, Food and Drug Administration. 2010. FDA's inactive ingredient database. Accessed March 9, 2011, at: http://www.fda.gov/Drugs/InformationOnDrugs/ucm113978.htm.
63. Neuvonen P. 1991. The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac. Br J Clin Pharmacol 31:263-266.
64. Stiegler S, Birkel M, Jost V, Lange R, Lücker PW, Wetzelsberger N. 1995. Pharmacokinetics and relative bioavailability after single dose administration of 25mg ketoprofen solution as compared to tablets. Methods Find Exp Clin Pharmacol 17:129-134.
65. Granero GE, Ramachandran C, Amidon GL. 2006. Rapid in vivo dissolution of ketoprofen: Implications on the Biopharmaceutics Classification System. Pharmazie 61(8):673-676.
66. Shohin IE, Kulinich JI, Ramenskaya GV, Vasilenko GF. 2011. Evaluation of in vitro equivalence for drugs containing BCS Class II compound ketoprofen. Diss Technol 19(1):26-29.
67. Wu C, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
68. Benet LZ, Amidon GL, Barends DM, Lennernäs H, Polli JE, Shah VP, Stavchansky SA, Yu LX. The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res 52(3):483-488.
69. Kovačevic I, Projčic J, Tubic-Grodzanis M, Langguth P. 2009. An investigation into the importance of "very rapid dissolution" criteria for drug bioequivalence demonstration using gastrointestinal simulation technology. AAPS J 11(2):381-384.
70. Blume H, Mutschler E. 1996. Bioäquivalenz, Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel, Teil I/II, Isosorbiddinitrat 6. Frankfurt/Main-Eschborn: Ergänzungslieferung, Govi-Verlag Pharmazeutischer Verlag.
71. Alvarez C, Núñez I, Torrado JJ, Gordon J, Potthast H, García-Arieta A. 2011. Investigation on the possibility of biowaivers for ibuprofen. J Pharm Sci 100(6):2343-2349.
72. Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ, Cancer Prevention Network. 2008. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev 17(3):674-679.
73. Chowdary C, Suresh Babu K. 1994. Dissolution, bioavailability and ulcerogenic studies on solid dispersions of indomethacin in water soluble cellulose polymers. Drug Dev Ind Pharm 20(5):799-813.
74. Benvenuti C, Gambaro V, Lodi F, Scaroni C, Bandi G, Valenti M. 1989. Single-dose pharmacokinetics of flurbiprofen granules and tablets in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 27:334-337.
75. Bareggi SR, Gambaro V, Valenti M, Benvenuti C. 1997. Absorption of oral lornoxicam in healthy volunteers using a granular formulation in comparison with standard tablets. Arzneimittelforschung 47(6):755-757.
76. Marzo A, Bo LD, Vergaf F, Ceppimontin N, Abbondatig G, Aleottitettamanti R, Crivellif F, Uhr MR, Ismaili S. 2000. Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. Arzneimittelforschung 50:43-47.
77. Piscitelli DA, Bigora S, Propst C, Goskonda S, Schwartz P, Lesko LJ, Augsburger L, Young D. 1998. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules. Pharm Dev Technol 3(4):443-452.
78. U.S. Food and Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). 2006. Dissolution method for drug products. Accessed June 1, 2011, at: http://www.accessdata.fda.gov/scripts/cder/dissolution.
79. Gleiter GH, Klotz U, Kuhlmann J, Blume H, Stanislaus F, Harder S, Paulus H, Poethko-Müller C, Holz-Slomczyk M. 1998. When are bioavailability studies required? A German proposal. J Clin Pharmacol 38:904-911.
80. Famaey JP. 1985. Correlation plasma levels, NSAID and therapeutic response. Clin Rheumatol 4(2):124-132.
81. Orme ML. 1985. The relationship between the plasma concentration of non-steroidal anti-inflammatory drugs and their therapeutic effects. Agents Actions Suppl 17:151-155.
82. Köhler G, Primbs P, Morand J, Rübelt C. 1985. Correlation between ketoprofen plasma levels and analgesic effect in acute lumbar pain and radicular pain. Clin Rheumatol 4(4):399-404.
83. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS. 2002. Biopharmaceutics Classification System: The scientific basis for biowaiver extensions. Pharm Res 19(7):921-925.
84. Polli JE, Yu LX, Cook JA, Amidon GL, Borchardt RT, Burnside BA, Burton PS, Chen ML, Conner DP, Faustino PJ, Hawi AA, Hussain AS, Joshi HN, Kwei G, Lee VH, Lesko LJ, Lipper RA, Loper AE, Nerurkar SG, Polli JW, Sanvordeker DR, Taneja R, Uppoor RS, Vattikonda CS, Wilding I, Zhang G. 2004. Summary workshop report: Biopharmaceutics Classification System-Implementation challenges and extension opportunities. J Pharm Sci 93(6):1375-1381.
85. Polli JE, Abrahamsson BS, Yu LX, Amidon GL, Baldoni JM, Cook JA, Fackler P, Hartauer K, Johnston G, Krill SL, Lipper RA, Malick WA, Shah VP, Sun D, Winkle HN, Wu Y, Zhang H. 2008. Summary workshop report: Bioequivalence, Biopharmaceutics Classification System, and beyond. AAPS J 10(2):373-9.